Kopran Ltd

Kopran's capital structure shows a debt-to-equity ratio of 0.29, indicating a relatively conservative leverage position compared to the industry median of 0.45. The company's liquidity position is mixed, with a current ratio of 1.76 but only INR 1.15 million in cash and equivalents, which is significantly lower than the INR 1.4 billion in long-term debt. This suggests potential liquidity risk despite the company's strong operating cash flow of INR 419.42 million. Profitability metrics show Kopran's return on equity (ROE) at 7.44%, below the industry median of 9.2%, and return on assets (ROA) at 4.57%, also below the median of 6.1%. The company's operating margin of 9.3% is in line with the industry median, but its net margin of 6.1% is slightly below the median of 6.8%, indicating some inefficiencies in cost management or tax optimization. Kopran's revenue is concentrated in its domestic operations, with no disclosed international revenue in the latest financials. The company's product portfolio is diversified across penicillin-based and non-penicillin-based formulations, but there is no segment-specific revenue breakdown provided in the input data. This lack of transparency limits the ability to assess the performance of individual product lines. The company's growth trajectory is modest, with no specific revenue growth rate provided in the input data. However, the free cash flow is negative at INR -192.36 million, driven by capital expenditures of INR -589.19 million. This suggests that Kopran is reinvesting heavily in its operations, which could support long-term growth but may also strain short-term liquidity. Risk factors include medium liquidity risk due to the negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the input data. However, the company's capital expenditures and negative free cash flow may necessitate future financing, which could introduce dilution pressure. Recent events include the company's continued focus on manufacturing a broad range of APIs and formulations, as disclosed in its latest financial filings. There are no specific recent events or transcripts provided in the input data that indicate significant changes in the company's strategic direction or operational performance.